Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London, UK; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK.
Periodontology/Oral and Mucosal Biology, Dental Institute, King's College London, London, UK.
Neurobiol Aging. 2018 Oct;70:125-127. doi: 10.1016/j.neurobiolaging.2018.06.014. Epub 2018 Jun 20.
There is a need for an accessible biomarker that can complement current cerebrospinal fluid and imaging biomarkers in an accurate and early diagnosis of Alzheimer disease (AD). Saliva is a rich source of potential biomarkers and proteins related to neurodegenerative disorders have been shown to be present in this matrix, including tau. In this study, we quantified salivary total tau (t-tau) concentration in 160 healthy elderly control, 68 mild cognitive impairment, and 53 AD participants using ultrasensitive Single molecule array (Simoa) technology. No median difference in salivary t-tau concentration was found between AD and mild cognitive impairment or healthy elderly control (12.3 ng/L, 9.8 ng/L and 9.6 ng/L, respectively, p = 0.219). In addition, there was no association of salivary t-tau concentration with neurophysiological assessment or structural magnetic resonance imaging. Despite a nominal increase in AD, due to the large overlaps in concentrations between clinical groups, we conclude that salivary t-tau is a suitable biomarker neither for AD nor for cognitive impairment.
目前需要一种易于获取的生物标志物，以补充当前的脑脊液和影像学生物标志物，实现对阿尔茨海默病（AD）的准确和早期诊断。唾液是潜在生物标志物的丰富来源，已有研究表明，与神经退行性疾病相关的蛋白质存在于该基质中，包括tau 蛋白。在这项研究中，我们使用超敏单分子阵列（Simoa）技术定量检测了 160 名健康老年对照组、68 名轻度认知障碍组和 53 名 AD 患者的唾液总 tau（t-tau）浓度。AD 组与轻度认知障碍组或健康老年对照组之间的唾液 t-tau 浓度中位数无差异（分别为 12.3ng/L、9.8ng/L 和 9.6ng/L，p=0.219）。此外，唾液 t-tau 浓度与神经生理学评估或结构磁共振成像无相关性。尽管 AD 患者的 t-tau 浓度略有升高，但由于临床组之间浓度存在较大重叠，我们得出结论，唾液 t-tau 既不适合用于 AD 诊断，也不适合用于认知障碍诊断。
